Orchard Therapeutics Announces Reimbursement Agreement in Spain
Portfolio Pulse from
Orchard Therapeutics, a Kyowa Kirin company, has secured a reimbursement agreement in Spain for its gene therapy Libmeldy®, providing access to eligible children with early-onset metachromatic leukodystrophy.
February 28, 2025 | 8:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Orchard Therapeutics has reached a reimbursement agreement in Spain for its gene therapy Libmeldy®, which will provide access to eligible children with early-onset metachromatic leukodystrophy.
The reimbursement agreement in Spain is a significant milestone for Orchard Therapeutics as it expands the market for Libmeldy®. This could lead to increased revenues and market presence in Europe, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100